BioPorto has entered into an agreement concerning the bulk purchase, packaging
and distribution of NGAL test reagent for Wiener Lab Group’s own analyzers in
Latin America. Wiener Lab Group has existed for more than 50 years and is a
market leader in analyzers for small and medium-sized laboratories in core
Latin American markets, such as Brazil and Argentina. Wiener Lab Group has
commenced the registration process for the purpose of obtaining certification
of an NGAL assay in Argentina and will subsequently register and market the
assay in the rest of Latin America. 



BioPorto’s sales strategy for its proprietary The NGAL Test is based on
establishing sales channels through local distributors and through global and
regional suppliers of analyzers. Since the launch of The NGAL Test, several of
the most important suppliers of analyzers have expressed an interest in working
together on distributing the immunoassay. Negotiations with several of the
biggest of these players concerning access to BioPorto’s The NGAL Test are in
progress. At the same time, BioPorto is continuing to develop its national
distribution networks, which already cover the most important markets in Europe
and the BRIC countries. 



The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences. 


         For further information, please contact:
         Thea Olesen, CEO
         Frank Harder, CFO
         Tel. +45 4529 0000, e-mail investor@bioporto.com